• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·3118.TWO
Share

Level Biotechnology Inc. Stocks

NT$ 30.7Last Updated 20.10.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 30.83M

NT$ 30.7
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immunology, and molecular biology, alongside advanced biomedical instrumentation, throughout Taiwan. Beyond product distribution, Level Biotechnology offers a comprehensive suite of research and testing services. These include expert assessments in mammalian and genetic toxicology, pharmacological studies, biocompatibility testing, and the production of model animals. The firm's preclinical research capabilities serve a diverse range of clients in the biotechnology, pharmaceutical, medical device, animal health, and agrichemical industries.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, under

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 09:54

Revolut has obtained a crypto license in Gibraltar. Why does this neobank need this jurisdiction?

20.10.2026 09:00

Analysts have expressed doubts about demand for the new iPhones. KeyBanc expects Apple's stock to fall 27%.

20.10.2026 08:00

U.S. defense companies fell 16%. Why is the market worried about a Democratic victory in the election?

20.10.2026 04:34

Anthropic is seeking an additional $45 billion in funding. The deal could support its partner Nvidia's IPO

20.10.2026 01:27

A Breather After the Plunge: Nasdaq Rebounded 1.2% as Demand for AI Stocks Returned

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026